Trial Profile

NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 24 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aldoxorubicin (Primary) ; Avelumab (Primary) ; Bevacizumab (Primary) ; Capecitabine (Primary) ; Cyclophosphamide (Primary) ; ETBX 011 (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; GI 4000 (Primary) ; High affinity CD-expressing natural killer cell therapy ImmunityBio (Primary) ; Nogapendekin alfa inbakicept (Primary) ; Omega-3-acid ethyl esters (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary)
Indications Adenocarcinoma; Pancreatic cancer
Focus Adverse reactions; Therapeutic Use
Sponsors ImmunityBio; NantKwest

21 May 2024 Status changed from active, no longer recruiting to discontinued.
29 Jan 2020 Results presented in the CytRx Corporation Media Release.
14 Jul 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com